The anti-tumor agent, p-DDAP potently suppresses proliferation through apoptosis in human neuroblastoma NB-39-nu cells

Cancer Letters

Volumn 297, Issue 2, 2010, Pages 252-258

  Takahashi, Noriko ^a   Egawa, Rumi ^a   Imai, Masahiko ^a   Takahashi, Katsuhiko ^a   Ohba, Toshihiro ^a   Imaizumi, Masue ^b  

^a HOSHI UNIVERSITY   (Japan)

^b MIYAGI CHILDREN S HOSPITAL   (Japan)

Author keywords

4 HPR; Apoptosis; Neuroblastoma; P DDAP; Retinoid

Indexed keywords

4 DODECYLAMINOAMINOPHENOL; ANTINEOPLASTIC AGENT; UNCLASSIFIED DRUG; AMINOPHENOL DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENCY; DRUG STRUCTURE; ENZYME ACTIVATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MORPHOLOGY; NEUROBLASTOMA; PRIORITY JOURNAL; CELL CYCLE; CELL GROWTH; DRUG EFFECTS; PATHOLOGY; TUMOR CELL LINE;

AMINOPHENOLS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL DIFFERENTIATION; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DOWN-REGULATION; HUMANS; NEUROBLASTOMA;

EID: 77956404384     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2010.05.018     Document Type: Article

References (22)

1. Niizuma H., Nakamura Y., Ozaki T., Nakanishi H., Ohira M., Isogai E., Kageyama H., Imaizumi M., Nakagawara A. Bcl-2 is a key regulator for the retinoic acid-induced apoptotic cell death in neuroblastoma. Oncogene 2006, 25:5046-5055.
2. Pearson A.D., Pinkerton C.R., Lewis I.J., Imeson J., Ellershaw C., Machin D. High-dose rapid and standard induction chemotherapy for patients aged over 1year with stage 4 neuroblastoma: a randomised trial. Lancet Oncol. 2008, 9:247-256.
3. Joshi S., Guleria R., Pan J., DiPette D., Singh U.S. Retinoic acid receptors and tissue-transglutaminase mediate short-term effect of retinoic acid on migration and invasion of neuroblastoma SH-SY5Y cells. Oncogene 2006, 25:240-247.
4. Mosse Y.P., Laudenslager M., Longo L., Cole K.A., Wood A., Attiyeh E.F., Laquaglia M.J., Sennett R., Lynch J.E., Perri P., Laureys G., Speleman F., Kim C., Hou C., Hakonarson H., Torkamani A., Schork N.J., Brodeur G.M., Tonini G.P., Rappaport E., Devoto M., Maris J.M. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 2008, 455:930-935.
5. Kushner B.H., Kramer K., Modak S., Qin L.X., Yataghena K., Jhanwar S.C., Cheung N.K. Reduced risk of secondary leukemia with fewer cycles of dose-intensive induction chemotherapy in patients with neuroblastoma. Pediatr. Blood Cancer 2009, 53:17-22.
6. Jiang M., Zhu K., Grenet J., Lahti J.M. Retinoic acid induces caspase-8 transcription via phospho-CREB and increases apoptotic responses to death stimuli in neuroblastoma cells. Biochim. Biophys. Acta 2008, 1783:1055-1067.
7. Matthay K.K., Villablanca J.G., Seeger R.C., Stram D.O., Harris R.E., Ramsay N.K., Swift P., Shimada H., Black C.T., Brodeur G.M., Gerbing R.B., Reynolds C.P. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's cancer group. New Engl. J. Med. 1999, 341:1165-1173.
8. Matthay K.K., Reynolds C.P., Seeger R.C., Shimada H., Adkins E.S., Haas-Kogan D., Gerbing R.B., London W.B., Villablanca J.G. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study. J. Clin. Oncol. 2009, 27:1007-1013.
9. Formelli F., Carsana R., Costa A., Buranelli F., Campa T., Dossena G., Magni A., Pizzichetta M. Plasma retinol level reduction by the synthetic retinoid fenretinide: a 1year follow-up study of breast cancer patients. Cancer Res. 1989, 49:6149-6152.
10. Garaventa A., Luksch R., Lo Piccolo M.S., Cavadini E., Montaldo P.G., Pizzitola M.R., Boni L., Ponzoni M., Decensi A., De Bernardi B., Bellani F.F., Formelli F. Phase I trial and pharmacokinetics of fenretinide in children with neuroblastoma. Clin. Cancer Res. 2003, 9:2032-2039.
11. Decensi A., Bruno S., Costantini M., Torrisi R., Curotto A., Gatteschi B., Nicolo G., Polizzi A., Perloff M., Malone W.F., et al. Phase IIa study of fenretinide in superficial bladder cancer. Using DNA flow cytometry as an intermediate end point. J. Natl. Cancer Inst. 1994, 86:138-140.
12. Decensi A., Torrisi R., Polizzi A., Gesi R., Brezzo V., Rolando M., Rondanina G., Orengo M.A., Formelli F., Costa A. Effect of the synthetic retinoid fenretinide on dark adaptation and the ocular surface. J. Natl. Cancer Inst. 1994, 86:105-110.
13. Modiano M.R., Dalton W.S., Lippman S.M., Joffe L., Booth A.R., Meyskens F.L. Phase II study of fenretinide (N-[4-hydroxyphenyl]retinamide) in advanced breast cancer and melanoma. Invest. New Drug 1990, 8:317-319.
14. Decensi A., Fontana V., Fioretto M., Rondanina G., Torrisi R., Orengo M.A., Costa A. Long-term effects of fenretinide on retinal function. Eur. J. Cancer 1997, 33:80-84.
15. Sun S.Y., Yue P., Lotan R. Induction of apoptosis by N-(4-hydroxyphenyl)retinamide and its association with reactive oxygen species, nuclear retinoic acid receptors, and apoptosis-related genes in human prostate carcinoma cells. Mol. Pharmacol. 1999, 55:403-410.
16. Takahashi N., Watanabe Y., Maitani Y., Yamauchi T., Higashiyama K., Ohba T. P-Dodecylaminophenol derived from the synthetic retinoid, fenretinide: antitumor efficacy in vitro and in vivo against human prostate cancer and mechanism of action. Int. J. Cancer 2008, 122:689-698.
17. Ishizawa M., Kobayashi Y., Miyamura T., Matsuura S. Simple procedure of DNA isolation from human serum. Nucleic Acids Res. 1991, 19:5792.
18. Abou-Issa H., Moeschberger M., el-Masry W., Tejwani S., Curley R.W., Webb T.E. Relative efficacy of glucarate on the initiation and promotion phases of rat mammary carcinogenesis. Anticancer Res. 1995, 15:805-810.
19. Ohshima M., Ward J.M., Wenk M.L. Preventive and enhancing effects of retinoids on the development of naturally occurring tumors of skin, prostate gland, and endocrine pancreas in aged male ACI/segHapBR rats. J. Natl. Cancer Inst. 1985, 74:517-524.
20. Schwartz G.K., Shah M.A. Targeting the cell cycle: a new approach to cancer therapy. J. Clin. Oncol. 2005, 23:9408-9421.
21. Cohen G.M. Caspases: the executioners of apoptosis. Biochem. J. 1997, 326:1-16.
22. Scaffidi C., Fulda S., Srinivasan A., Friesen C., Li F., Tomaselli K.J., Debatin K.M., Krammer P.H., Peter M.E. Two CD95 (APO-1/Fas) signaling pathways. EMBO J. 1998, 17:1675-1687.